InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
MWN-AI** Summary
InspireMD, Inc. (Nasdaq: NSPR), a developer of innovative medical devices focused on stroke prevention, has announced the appointment of Dr. Peter A. Soukas as Chief Medical Officer. This strategic addition to InspireMD's leadership team is aimed at enhancing the company's mission to improve carotid intervention through the delivery of its CGuard® Prime carotid stent system. CEO Marvin Slosman expressed enthusiasm for Dr. Soukas's extensive expertise in vascular medicine, which is expected to be a significant asset as the company prepares to launch CGuard Prime in the U.S. market.
Dr. Soukas comes to InspireMD with a robust background in vascular technology and clinical practice. He holds the position of Director of Vascular Medicine and leads the Peripheral Vascular Interventional Laboratory at The Miriam Hospital. Additionally, he is an Associate Professor of Medicine at Brown University and has established a fellowship program in vascular and endovascular medicine. His credentials include being a Fellow of several prominent medical societies, showcasing his leadership within the interventional cardiovascular community.
Dr. Soukas has a distinguished record as a principal investigator in over 24 carotid stenting trials and has spoken at more than 300 lectures, solidifying his role as a thought leader in the field. His commitment is not only to advance the CGuard Prime stent technology but also to engage and collaborate with clinical partners to improve patient outcomes.
In his new role, Dr. Soukas aims to oversee clinical and medical strategies, ensuring that InspireMD remains at the forefront of innovation in carotid stenting technology. His focus will be on fostering partnerships that drive advancements in patient care and solidify InspireMD's position in the medical device sector.
MWN-AI** Analysis
InspireMD, Inc.'s recent appointment of Dr. Peter A. Soukas as Chief Medical Officer is a noteworthy development, signaling a potentially transformative phase for the company, especially as it pushes to dominate the U.S. carotid stent market with its CGuard Prime platform. Dr. Soukas brings a wealth of clinical experience and recognized expertise in vascular intervention, which bodes well for InspireMD’s strategic goals.
From a market perspective, this appointment could serve multiple purposes. Dr. Soukas' extensive background—including his role as director at The Miriam Hospital and substantial involvement in over 150 endovascular trials—positions him as a pivotal figure capable of enhancing the company’s clinical outreach and credibility. By leveraging his relationships with key opinion leaders and his commitment to improving patient outcomes, InspireMD can expect not only to increase visibility for its CGuard Prime system but also to foster partnerships that may lead to collaborative research and development opportunities.
Investors should view this leadership change as a potential catalyst for growth. InspireMD is joining a competitive sector that demands innovation and excellence, and Dr. Soukas' proven track record in advancing vascular technology may facilitate the company’s goal of establishing a leading position in the market. Additionally, as the demand for advanced medical devices continues to grow, especially in stroke prevention, InspireMD might see an uptick in interest from institutional investors looking for solid players in the healthcare technology space.
Despite potential volatility inherent in biotech companies during this period of expansion, prudent investors may consider taking a closer look at InspireMD (NASDAQ: NSPR). The alignment of strategic leadership with clinical expertise could enhance the likelihood of successful product launches and scalable growth, underpinning long-term value for shareholders. Keeping an eye on upcoming developments and market responses will be crucial as Dr. Soukas settles into his role and begins to implement his vision for InspireMD.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention.
“We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company,” said Marvin Slosman, Chief Executive Officer of InspireMD. “His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insights as we launch CGuard Prime into the U.S. market. Dr. Soukas has been a strong supporter of our work advancing our next generation CGuard Prime stent platform to transform patient care through best-in-class clinical outcomes. This transformational time for carotid intervention requires us to build a team to lead the field, and Dr. Soukas will be a tremendous contributor to our work ahead.”
Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice.
Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation.
“I'm honored to join InspireMD as Chief Medical Officer. As a physician, I've witnessed firsthand the devastating impact of stroke and the transformative difference that innovations like CGuard Prime can make for patients,” said Dr. Soukas. “Physicians depend on the partnership with industry to advance new innovation and the team at InspireMD is an incredible example of how this ecosystem works well. My commitment is to guide the company with oversight of clinical and medical topics that build on success to date while establishing greater awareness of this breakthrough stent platform. I'm excited to join this team while continuing to collaborate with our clinical partners to advance patient care.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com .
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ**
How does InspireMD Inc. NSPR plan to leverage Dr. Soukas' expertise in vascular intervention to enhance the adoption of the CGuard Prime stent system in the U.S. market?
What specific strategies will Dr. Soukas implement as Chief Medical Officer to ensure that InspireMD Inc. NSPR maintains its competitive edge in the carotid intervention market?
Can you detail any upcoming clinical trials or research studies that InspireMD Inc. NSPR plans to undertake under Dr. Soukas’ leadership to validate the effectiveness of the CGuard Prime stent?
How does InspireMD Inc. NSPR intend to communicate its advancements and results related to the CGuard Prime stent platform to investors and the medical community?
**MWN-AI FAQ is based on asking OpenAI questions about InspireMD Inc. (NASDAQ: NSPR).
NASDAQ: NSPR
NSPR Trading
0.3% G/L:
$1.65 Last:
15,727 Volume:
$1.65 Open:
